Predictors of survival from urachal cancer

Molina, Julian R.; Quevedo, J. Fernando; Furth, Alfred; Richardson, Ronald L.; Zincke, Horst; Burch, Patrick A.

doi:10.1002/cncr.23070

Cited by 149 publications

(213 citation statements)

References 18 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…All recurrences were at distant metastatic sites, with the lung being the most common. This result was in agreement with previous studies [27]. …”

Section: Discussionsupporting

confidence: 94%

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Jung¹,

Sun²,

Park³

et al. 2014

Chemotherapy

View full text Add to dashboard Cite

Background: Urachal cancer is a rare malignancy that accounts for <1% of bladder cancers. There is currently no consensus on the diagnosis and management of urachal cancer and there are very few reports on palliative chemotherapy for unresectable disease. We delineate the clinical features and treatment outcome of urachal cancer, in particular the relevance of palliative chemotherapy in recurrent, metastatic disease. Methods: The clinicopathologic variables and treatment outcome of patients who were treated for urachal cancer were retrospectively reviewed. Results: Among 28 eligible patients, 25 had localized disease and 3 had metastatic disease at initial diagnosis. All patients with localized disease underwent curative resection and there was disease recurrence in 10. Out of 13 patients with metastatic disease either at initial diagnosis or during follow-up, the lung was the most common metastatic site (n = 5), followed by the liver, bone and peritoneum. Ten patients received palliative chemotherapy. A total of 24 chemotherapeutic regimens were administered; regimens with a base of fluoropyrimidine (5-FU), taxane and gemcitabine were the most common. The overall response rate of all chemotherapeutic regimens was 16.7%. The 5-FU-based regimens showed a good response, with 2 of 4 patients who received these showing a partial response. One tumor with a partial small-cell component showed a partial response to both an etoposide-based regimen and a taxane-based regimen. Conclusions: In urachal cancer, curative surgery is still the recommended treatment with respect to overall survival. A 5-FU-based chemotherapy regimen could be considered for metastatic recurrent disease. © 2014 S. Karger AG, Basel

show abstract

“…All recurrences were at distant metastatic sites, with the lung being the most common. This result was in agreement with previous studies [27]. …”

Section: Discussionsupporting

confidence: 94%

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Jung¹,

Sun²,

Park³

et al. 2014

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Molina et al conducted a retrospective study on urachal carcinoma including 49 patients and found that 89% were adenocarcinomas, whereas sarcomas and transitional cell carcinomas represented ~4%. Of the adenocarcinomas, 63.6% may produce mucin (10). The result is similar to those of Paner et al (11).…”

Section: Discussionsupporting

confidence: 88%

Urachal carcinoma: Report of two cases and review of the literature

Quan

Pan

Jin

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Urachal carcinoma is a rare tumor that most commonly occurs in ovaries and less often in the adnexal region and urinary system. We herein present two cases of urachal carcinoma: One case was a 32-year-old male patient who presented with painless hematuria with blood clots for 1 month, whereas the other case was a 50-year-old woman who presented with gross hematuria with mild dysuria, urgency and frequent urination for 1 year. Following surgical resection, the two patients were diagnosed with urachal adenocarcinoma (mixed type) and urachal mucinous adenocarcinoma, respectively, based on the histopathological examination. A review of previously published cases and relevant literature is also presented. The aim of the present study was to help understand this disease better, in order to reduce the rate of clinical and pathological misdiagnosis. IntroductionUrachal carcinoma is a rare non-urothelial carcinoma, accounting for 0.01% of all malignancies and for 0.17-0.34% of all bladder tumors (1,2). Urachal carcinoma is more common among men, and the majority of the patients are aged >50 years (3). Although hematuria is the most common symptom, the disease is usually advanced when this symptom appears (4). As urachal carcinoma frequently invades the bladder at the dome or elsewhere along its midline, which is not easily detected during the early stages, it is often discovered late (5). Furthermore, there is currently no effective treatment for urachal carcinoma, leading to a poor prognosis. We herein report the cases of two patients with urachal carcinoma and urachal mucinous carcinoma. The relevant literature was also reviewed in order to help improve the diagnosis and treatment of this rare disease. Case reportsCase 1. The patient was a 32-year-old man who noted painless hematuria with blood clots for 1 month. There were no obvious precipitating or alleviating factors. On physical examination, there were no positive physical findings and the patient experienced no other discomfort. The results of the laboratory and imaging examinations (hemogram, urinalysis, prothrombin time, activated partial thromboplastin time, liver and kidney function tests and chest X-ray) were normal. However, urinary tract ultrasonography revealed an abnormal mixed signal at the bottom of the bladder. On further cystoscopy, only a small blood clot was detected. However, computed tomography (CT) revealed a circular hypodense mass located at the top and anterior part of the bladder, sized ~44x43 mm, without enlarged lymph nodes or other sign of metastatic disease (Fig. 1A).Following the doctors' recommendation, the patient consented to radical resection of the urachal tumor and partial cystectomy in August, 2015. We found that the lower part of the tumor was connected to the anterior wall of the bladder, whereas the upper part of the tumor was connected with the umbilical region. The tumor was sized ~7x8 cm. On gross pathological examination, the resected specimen was grey-yellow and gray-red, with a diameter of 6 cm. A small area co...

show abstract

“…The prognosis of patients with urachal cancer is generally considered poor because it is generally diagnosed at an advanced disease stage and is associated with a high frequency of recurrence after primary treatment. The 5-year overall survival (OS) is reported to be 34-40% [2,3]. In particular, the median survival time for stage IV patients (metastatic disease) is 1.3 years compared with a median survival of 10.8 years for stage I/II patients [3].…”

Section: Introductionmentioning

confidence: 99%

“…The 5-year overall survival (OS) is reported to be 34-40% [2,3]. In particular, the median survival time for stage IV patients (metastatic disease) is 1.3 years compared with a median survival of 10.8 years for stage I/II patients [3]. …”

Section: Introductionmentioning

confidence: 99%

Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer

et al. 2013

View full text Add to dashboard Cite

Background: To improve the prognosis of patients with urachal cancer and establish an effective chemotherapeutic regimen for distant metastases. Methods: We conducted a retrospective study to evaluate the efficacy and safety of a modified combination of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) therapy in patients with metastatic urachal cancer. Results: Five patients were treated with mFOLFOX6. Their median age was 65 years (range 41-80). The median follow-up time was 42 months (range 18-46). Two of the 5 patients (40%) showed an objective response: 1 achieved a clinically complete response and 1 a partial response. The grade 3/4 toxicity associated with this regimen was primarily neutropenia, but febrile neutropenia was not observed. Oxaliplatin treatment was discontinued because of a grade 2 allergic reaction in 1 patient. Grade 2 peripheral sensory neuropathy caused by oxaliplatin was observed in 2 patients, and the OPTIMOX (stop and go) approach had to be adopted. Conclusions: mFOLFOX6 appears to be effective for the treatment of metastatic urachal cancer.

show abstract

Predictors of survival from urachal cancer

Cited by 149 publications

References 18 publications

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Urachal carcinoma: Report of two cases and review of the literature

Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer

Contact Info

Product

Resources

About